<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fourteen children treated by L-Asparaginase for <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> had sequential coagulation studies performed including cephalin-kaolin time, Quick time, fibrinogen, factors II, VII + X and V, as well as antithrombin III and protein C, the major coagulation inhibitors </plain></SENT>
<SENT sid="1" pm="."><plain>A severe antithrombin III and <z:hpo ids='HP_0005543'>protein C deficiency</z:hpo> was observed during therapy, with a coexisting hypocoagulability </plain></SENT>
<SENT sid="2" pm="."><plain>This equilibrium partially explains the lack of thrombo-embolic phenomena in these children, despite the risk factors present </plain></SENT>
<SENT sid="3" pm="."><plain>Although no substitutive therapy was instituted in these cases, their use in high-risk cases is discussed </plain></SENT>
</text></document>